Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DB-1305 |
| Synonyms | |
| Therapy Description |
DB-1305 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting TROP2 conjugated to a DNA topoisomerase I inhibitor, which potentially results in antitumor activity (Ann Oncol 34 (2023): S480). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DB-1305 | DB1305|DB 1305|BNT325|BNT 325|BNT-325 | TROP2 Antibody 18 | DB-1305 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting TROP2 conjugated to a DNA topoisomerase I inhibitor, which potentially results in antitumor activity (Ann Oncol 34 (2023): S480). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05438329 | Phase Ib/II | DB-1305 BNT327 + DB-1305 DB-1305 + Pembrolizumab | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Recruiting | USA | 2 |